Insmed (NASDAQ:INSM) Stock Price Down 3.4% Following Insider Selling

Key Points

• Insmed's stock (NASDAQ: INSM) fell by 3.4% during mid-day trading, marking a significant decline from the previous closing price, with unusually low trading volume.
• Analysts maintain a consensus rating of "Moderate Buy" for Insmed with a consensus price target of $139.86, indicating positive outlook despite recent stock performance.
• The company reported a quarterly loss of ($1.70) earnings per share, missing expectations, but showed an 18.9% increase in revenue year-over-year.

Insmed, Inc. (NASDAQ:INSM - Get Free Report)'s share price was down 3.4% on Monday following insider selling activity. The stock traded as low as $143.84 and last traded at $141.03. Approximately 54,412 shares changed hands during trading, a decline of 98% from the average daily volume of 2,753,988 shares. The stock had previously closed at $145.93.

Specifically, Director Melvin Md Sharoky sold 10,000 shares of the company's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director directly owned 262,675 shares of the company's stock, valued at $38,190,318.25. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the completion of the sale, the insider owned 36,461 shares of the company's stock, valued at approximately $5,303,252.45. This represents a 67.73% decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

INSM has been the subject of several research reports. Guggenheim increased their price target on shares of Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research report on Monday, September 8th. Royal Bank Of Canada increased their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Bank of America increased their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Morgan Stanley increased their price target on shares of Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Truist Financial lifted their price target on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Sixteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $139.86.

Insmed Trading Down 0.8%

The stock has a fifty day moving average of $124.17 and a 200 day moving average of $94.19. The company has a market capitalization of $30.60 billion, a P/E ratio of -25.35 and a beta of 0.97. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period last year, the company earned ($1.94) EPS. The business's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cullen Frost Bankers Inc. grew its position in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP purchased a new position in shares of Insmed during the fourth quarter valued at $28,000. ORG Partners LLC grew its holdings in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares in the last quarter. Hilltop National Bank purchased a new position in Insmed during the 2nd quarter valued at about $28,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Insmed in the 2nd quarter worth approximately $33,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.